- MGC Pharmaceuticals (MXC) begins a clinical study on patients with Long COVID syndrome in Spain
- MGC Pharma is co-sponsoring the study, along with partners Swiss PharmaCan AG and Glow LifeTech, which will investigate the efficacy of its supplement, ArtemiC Support over a six-week period
- The study was given the green light for ethics committee approval and is now underway, with 50 of the targeted 150 patients enrolled
- The trial is expected to wrap up in February 2022, subject to enrolment targets being achieved, with a potential further study to follow
- MGC Pharmaceuticals last traded at 3.7 cents on December 20
MGC Pharmaceuticals (MXC) has begun a clinical study on patients with Long COVID syndrome in Spain.
Long COVID or post-acute COVID syndrome refers to the ongoing health problems often experienced four or more weeks after a patient is first infected with SARS-CoV-2, which affects up to 35 per cent of all COVID patients. Symptoms of the syndrome include shortness of breath, lack of energy, loss of smell, a cough, headache and mental confusion.
MGC Pharma is co-sponsoring the study, along with partners Swiss PharmaCan AG and Glow LifeTech, which will investigate its supplement, ArtemiC Support.
The study was given the green light for the ethics committee approval and is now underway, with 50 of the targeted 150 patients enrolled.
Patients will be dosed with ArtemiC Support for six weeks under supervision of their doctor.
The ArtemiC Support study is expected to wrap up in February 2022, subject to enrolment targets being achieved.
The trial follows a 2020 study which saw MGC Pharma determine the efficacy of ArtemiC in patients diagnosed with moderate COVID-19.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, said the study is a crucial first step in determining whether ArtemiC Support helps Long COVID sufferers by treating what often are very debilitating conditions.
“Working with our partners Swiss PharmaCan and Glow LifeTech, we are hopeful that this study will demonstrate that ArtemiC Support is as successful at helping patients with Long COVID, as the Phase II study undertaken in 2020 indicated that ArtemiC™ was in treating patients with moderate COVID-19,” said Mr Zomer.
Depending on the outcome of the study, a further randomised, placebo-controlled study on ArtemiC Support for patients suffering Long COVID Syndrome will follow.
MGC Pharmaceuticals last traded at 3.7 cents on December 20.